ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

18 links0 made here, not in the record41 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03899155Pan Tumor Rollover StudyBristol-Myers SquibbPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 30 · ClinicalTrials.gov record · Version of 2026-10-30Nov 6 · ClinicalTrials.gov record · Version of 2026-11-06Version of 2026-11-06CONDITIONSNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseAs of now · Rule based · Main conditionMain conditionDRUGSNivolumabIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIpilimumabIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerCabozantinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrametinibIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundRelatlimabIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundNov 18 · Rule based · TestedTestedCapecitabineIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedBevacizumabIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTemozolomideIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundRucaparibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDaratumumabIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundLeucovorinIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundFluorouracilIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOxaliplatinIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEnzalutamideIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSunitinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPemetrexedIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Nivolumab

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Nivolumab”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Tested
Tested · 3

All judgments on this study

WhenLinkJudgeDecisionState
Oct 30The record itselfClinicalTrials.gov recordVersion of 2026-10-30Record change
Nov 1NivolumabClaude Opus 5.5TestedReplaced
Nov 1IpilimumabClaude Opus 5.5BackgroundReplaced
Nov 1CabozantinibClaude Opus 5.5TestedReplaced
Nov 1TrametinibClaude Opus 5.5BackgroundCurrent
Nov 1RelatlimabClaude Opus 5.5TestedCurrent
Nov 1CapecitabineClaude Opus 5.5TestedCurrent
Nov 1BevacizumabClaude Opus 5.5TestedCurrent
Nov 1TemozolomideClaude Opus 5.5BackgroundCurrent
Nov 1RucaparibClaude Opus 5.5TestedReplaced
Nov 1DaratumumabClaude Opus 5.5BackgroundCurrent
Nov 1LeucovorinClaude Opus 5.5BackgroundCurrent
Nov 1FluorouracilClaude Opus 5.5TestedCurrent
Nov 1OxaliplatinClaude Opus 5.5TestedCurrent
Nov 1EnzalutamideClaude Opus 5.5TestedCurrent
Nov 1SunitinibClaude Opus 5.5TestedCurrent
Nov 1PemetrexedClaude Opus 5.5TestedCurrent
Nov 1PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 2IpilimumabClaude Opus 5.5Background · partnerCurrent
Nov 2CabozantinibClaude Opus 5.5TestedCurrent
Nov 2RucaparibClaude Opus 5.5TestedCurrent
Nov 6The record itselfClinicalTrials.gov recordVersion of 2026-11-06Record change
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18NivolumabRule based · role ruleTestedAgrees
Nov 18IpilimumabRule based · role ruleBackgroundAgrees
Nov 18CabozantinibRule based · role ruleTestedAgrees
Nov 18TrametinibRule based · role ruleBackgroundAgrees
Nov 18RelatlimabRule based · role ruleBackgroundOverridden
Nov 18RelatlimabRule based · role ruleTestedAgrees
Nov 18CapecitabineRule based · role ruleTestedAgrees
Nov 18BevacizumabRule based · role ruleTestedAgrees
Nov 18TemozolomideRule based · role ruleBackgroundAgrees
Nov 18RucaparibRule based · role ruleTestedAgrees
Nov 18DaratumumabRule based · role ruleBackgroundAgrees
Nov 18LeucovorinRule based · role ruleTestedOverridden
Nov 18FluorouracilRule based · role ruleTestedAgrees
Nov 18OxaliplatinRule based · role ruleTestedAgrees
Nov 18EnzalutamideRule based · role ruleTestedAgrees
Nov 18SunitinibRule based · role ruleTestedAgrees
Nov 18PemetrexedRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleTestedOverridden
As of nowNeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.